JP7225125B2 - ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物 - Google Patents

ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物 Download PDF

Info

Publication number
JP7225125B2
JP7225125B2 JP2019567574A JP2019567574A JP7225125B2 JP 7225125 B2 JP7225125 B2 JP 7225125B2 JP 2019567574 A JP2019567574 A JP 2019567574A JP 2019567574 A JP2019567574 A JP 2019567574A JP 7225125 B2 JP7225125 B2 JP 7225125B2
Authority
JP
Japan
Prior art keywords
mmol
methoxy
pharmaceutically acceptable
acceptable salt
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523315A (ja
JP2020523315A5 (enExample
Inventor
チョル・ユ
ミン・ユ
マヌエル・ザンカネラ
ジョァ・リ
Original Assignee
グローバル ブラッド セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローバル ブラッド セラピューティクス インコーポレイテッド filed Critical グローバル ブラッド セラピューティクス インコーポレイテッド
Publication of JP2020523315A publication Critical patent/JP2020523315A/ja
Publication of JP2020523315A5 publication Critical patent/JP2020523315A5/ja
Application granted granted Critical
Publication of JP7225125B2 publication Critical patent/JP7225125B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019567574A 2017-06-09 2018-06-07 ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物 Active JP7225125B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517410P 2017-06-09 2017-06-09
US62/517,410 2017-06-09
PCT/US2018/036521 WO2018226998A1 (en) 2017-06-09 2018-06-07 Azaindole compounds as histone methyltransferase inhibitors

Publications (3)

Publication Number Publication Date
JP2020523315A JP2020523315A (ja) 2020-08-06
JP2020523315A5 JP2020523315A5 (enExample) 2021-07-26
JP7225125B2 true JP7225125B2 (ja) 2023-02-20

Family

ID=62779058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567574A Active JP7225125B2 (ja) 2017-06-09 2018-06-07 ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物

Country Status (11)

Country Link
US (2) US11111243B2 (enExample)
EP (1) EP3634962B1 (enExample)
JP (1) JP7225125B2 (enExample)
CN (1) CN110997671A (enExample)
AR (1) AR112192A1 (enExample)
BR (1) BR112019025770A2 (enExample)
ES (1) ES2949402T3 (enExample)
IL (1) IL271066A (enExample)
MX (1) MX2019014759A (enExample)
TW (1) TW201920165A (enExample)
WO (1) WO2018226998A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.
JP7749679B2 (ja) * 2021-02-05 2025-10-06 シンノハブ ファーマシューティカル カンパニー,リミティド プラスミン阻害剤、その製造方法およびその適用
CN114394971B (zh) * 2022-01-24 2023-01-31 云南大学 一种吲哚咔唑类化合物的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527394A (ja) 2000-03-15 2003-09-16 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ベーターカルボリン
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
JP2013533239A (ja) 2010-06-25 2013-08-22 ファキュルテ ユニヴェルシテール ノートル−ダム ド ラ ペ 増殖性疾患の治療に有用なβカルボリン誘導体

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
RU2532135C2 (ru) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Производные иминопиридина и их применение в качестве микробиоцидов
AU2008343932B2 (en) * 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PL2364983T3 (pl) 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
TW201236880A (en) 2011-03-11 2012-09-16 Primax Electronics Ltd Sheet feeding apparatus
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US9284272B2 (en) 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
US10407423B2 (en) 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003527394A (ja) 2000-03-15 2003-09-16 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ベーターカルボリン
WO2008055233A1 (en) 2006-10-31 2008-05-08 Supergen, Inc. Protein kinase inhibitors
JP2013533239A (ja) 2010-06-25 2013-08-22 ファキュルテ ユニヴェルシテール ノートル−ダム ド ラ ペ 増殖性疾患の治療に有用なβカルボリン誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS Chem. Biol.,2013年,8,543-548
ACS Med. Chem. Lett.,2014年,5,205-209
J. Med. Chem.,2013年,56,8931-8942

Also Published As

Publication number Publication date
AR112192A1 (es) 2019-10-02
JP2020523315A (ja) 2020-08-06
IL271066A (en) 2020-01-30
CN110997671A (zh) 2020-04-10
EP3634962A1 (en) 2020-04-15
EP3634962B1 (en) 2023-05-24
TW201920165A (zh) 2019-06-01
WO2018226998A1 (en) 2018-12-13
US20180354947A1 (en) 2018-12-13
ES2949402T3 (es) 2023-09-28
US20210371417A1 (en) 2021-12-02
MX2019014759A (es) 2020-02-12
US11111243B2 (en) 2021-09-07
BR112019025770A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
JP7755632B2 (ja) 統合的ストレス経路のモジュレーター
JP2024045176A (ja) メニン-mll相互作用の阻害剤
EP3452453B1 (en) Modulators of the integrated stress pathway
US10246462B2 (en) Chemokine receptor modulators and uses thereof
US10864196B2 (en) Modulators of the integrated stress pathway
JP2022137047A (ja) ヒストンメチルトランスフェラーゼ阻害剤
JP7267993B2 (ja) ヒストンメチルトランスフェラーゼ阻害剤としての三環式化合物
JP2019511472A (ja) ヒストンメチルトランスフェラーゼ阻害剤
US20210371417A1 (en) Azaindole compounds as histone methyltransferase inhibitors
OA19439A (en) Azaindole compounds as histone methyltranferase inhibitors.
OA19495A (en) Tricyclic compounds as Histone Methyltransferase inhibitors.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210603

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7225125

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150